Is ARXRF or JNJ a better dividend investment in 2026?

ARXRF currently yields 16666.67% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: ARXRF offers higher current income.

What is the dividend yield difference between ARXRF and JNJ?

ARXRF has a forward dividend yield of 16666.67% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 16664.54 percentage points.

Home › Compare › ARXRF vs JNJ

ARXRF vs JNJ: Dividend Comparison 2026

ARXRF yields 16666.67% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ARXRF wins by $8601297707047409664.00M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ARXRF

● Live price

16666.67%

Share price

$0.01

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8601297707047409664.00M

Annual income

$8,500,961,637,704,150,000,000,000.00

Full ARXRF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — ARXRF vs JNJ

📍 ARXRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ARXRF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ARXRF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ARXRF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARXRF

Annual income on $10K today (after 15% tax)

$1,416,666.67/yr

After 10yr DRIP, annual income (after tax)

$7,225,817,392,048,527,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, ARXRF beats the other by $7,225,817,392,048,527,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARXRF + JNJ for your $10,000?

ARXRF: 50%JNJ: 50%

100% JNJ50/50100% ARXRF

Portfolio after 10yr

$4300648853523704832.00M

Annual income

$4,250,480,818,852,075,000,000,000.00/yr

Blended yield

98.83%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ARXRF

No analyst data

Altman Z

12.8

Piotroski

1/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARXRF buys

JNJ buys

No recent congressional trades found for ARXRF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricARXRFJNJ

Forward yield	16666.67% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$8601297707047409664.00M ✓	$30.3K
Annual income after 10y	$8,500,961,637,704,150,000,000,000.00 ✓	$4,689.40
Total dividends collected	$8594666089931243520.00M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: ARXRF vs JNJ ($10,000, DRIP)

Year	ARXRF Portfolio	ARXRF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$1,677,367	$1,666,666.67	$10,592	$272.30	+$1.67M → ARXRF
2	$263,066,849	$261,272,066.46	$11,289	$357.73	+$263.06M → ARXRF
3	$38,576,943,838	$38,295,462,310.00	$12,123	$472.89	+$38576.93M → ARXRF
4	$5,289,656,888,585	$5,248,379,558,677.81	$13,141	$629.86	+$5289656.88M → ARXRF
5	$678,235,585,150,030	$672,575,652,279,244.40	$14,408	$846.81	+$678235585.14M → ARXRF
6	$81,321,145,183,775,540	$80,595,433,107,665,010.00	$16,021	$1,151.60	+$81321145183.76M → ARXRF
7	$9,118,299,079,523,715,000	$9,031,285,454,177,076,000.00	$18,122	$1,588.22	+$9118299079523.70M → ARXRF
8	$956,159,646,381,740,000,000	$946,403,066,366,649,700,000.00	$20,930	$2,228.20	+$956159646381740.00M → ARXRF
9	$93,772,027,423,605,150,000,000	$92,748,936,601,976,690,000,000.00	$24,792	$3,191.91	+$93772027423605152.00M → ARXRF
10	$8,601,297,707,047,409,000,000,000	$8,500,961,637,704,150,000,000,000.00	$30,274	$4,689.40	+$8601297707047409664.00M → ARXRF

ARXRF vs JNJ: Complete Analysis 2026

ARXRF — Stock

Imagine Lithium Inc., a junior mineral exploration company, acquires, explores, and evaluates mineral properties in North America. Its flagship project is the 100% owned Jackpot Lithium property located in Thunder Bay, Ontario. The company was formerly known as Infinite Ore Corp. and changed its name to Imagine Lithium Inc. in February 2022. Imagine Lithium Inc. is headquartered in Vancouver, Canada.

Full ARXRF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this ARXRF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARXRF vs SCHD ARXRF vs JEPI ARXRF vs O ARXRF vs KO ARXRF vs MAIN ARXRF vs ABBV ARXRF vs MRK ARXRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.